DK4516357T3 - Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf - Google Patents

Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf

Info

Publication number
DK4516357T3
DK4516357T3 DK24204055.8T DK24204055T DK4516357T3 DK 4516357 T3 DK4516357 T3 DK 4516357T3 DK 24204055 T DK24204055 T DK 24204055T DK 4516357 T3 DK4516357 T3 DK 4516357T3
Authority
DK
Denmark
Prior art keywords
antitumormore
preparing
compound
antitumormore compound
Prior art date
Application number
DK24204055.8T
Other languages
Danish (da)
English (en)
Inventor
Yu Zhang
Zhongyuan Zhu
Haiqing Hua
Bing Li
Jian Li
Shengchao Lin
Xi Li
Hongxia Shen
Original Assignee
Duality Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duality Biologics Suzhou Co Ltd filed Critical Duality Biologics Suzhou Co Ltd
Application granted granted Critical
Publication of DK4516357T3 publication Critical patent/DK4516357T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK24204055.8T 2020-09-30 2021-09-29 Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf DK4516357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011061580 2020-09-30
EP21874533.9A EP4223318A4 (en) 2020-09-30 2021-09-29 Antitumor compound, and preparation method therefor and use thereof

Publications (1)

Publication Number Publication Date
DK4516357T3 true DK4516357T3 (da) 2026-04-27

Family

ID=80951198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK24204055.8T DK4516357T3 (da) 2020-09-30 2021-09-29 Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf

Country Status (14)

Country Link
US (7) US11685742B2 (https=)
EP (2) EP4223318A4 (https=)
JP (1) JP2023551355A (https=)
KR (1) KR20230079085A (https=)
CN (5) CN121944137A (https=)
AU (1) AU2021354823A1 (https=)
CA (1) CA3195515A1 (https=)
DK (1) DK4516357T3 (https=)
FI (1) FI4516357T3 (https=)
IL (1) IL301793A (https=)
LT (1) LT4516357T (https=)
MX (1) MX2023003778A (https=)
TW (1) TW202214230A (https=)
WO (1) WO2022068878A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551355A (ja) * 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド 抗腫瘍化合物並びにその調製方法及び使用
GEAP202416409A (en) 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof
CN115557962A (zh) * 2021-07-02 2023-01-03 石药集团巨石生物制药有限公司 新型喜树碱类化合物及其制备方法和应用
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN115850291B (zh) * 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118829450A (zh) * 2022-01-18 2024-10-22 甘李药业股份有限公司 一种依喜替康衍生物-抗体偶联物及其医药用途
TW202341984A (zh) * 2022-01-28 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Ｈｅｒ３抗體藥物偶聯物及其用途
EP4489790A1 (en) * 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
WO2023174401A1 (zh) * 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Gpc3抗体药物偶联物及其用途
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药（苏州）有限公司 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
CN119384296A (zh) * 2022-06-07 2025-01-28 映恩生物制药（苏州）有限公司 抗b7h3抗体-药物偶联物及其用途
IL318296A (en) 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-TROP2 antibody and its conjugate
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
JP2025526504A (ja) * 2022-07-29 2025-08-13 杭州愛科瑞思生物医薬有限公司 エキサテカン誘導体及びその使用
US20240116945A1 (en) * 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
KR20250069963A (ko) * 2022-09-30 2025-05-20 베이진 스위찰랜드 게엠베하 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도
WO2024078449A1 (en) * 2022-10-09 2024-04-18 LaNova Medicines Limited Compounds, compositions and methods
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024098066A1 (en) * 2022-11-04 2024-05-10 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
CN119947761B (zh) * 2022-12-27 2026-03-03 映恩生物科技(上海)有限公司 抗b7h3和pd-l1的双特异性抗体药物偶联物及其制备方法和用途
AU2023417911A1 (en) * 2022-12-28 2025-05-29 Adcendo Aps Antibody-drug conjugates targeting uparap comprising exatecan derivatives
CN116712561A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
WO2024193692A1 (zh) 2023-03-22 2024-09-26 映恩生物制药（苏州）有限公司 连接子及其在配体药物偶联物中的应用
JPWO2024214685A1 (https=) 2023-04-10 2024-10-17
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025031286A1 (zh) * 2023-08-04 2025-02-13 映恩生物制药（苏州）有限公司 抗体药物偶联物的识别抗体及其应用
WO2025166725A1 (en) 2024-02-08 2025-08-14 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
AR133816A1 (es) 2023-09-15 2025-11-05 Duality Biologics Suzhou Co Ltd Conjugado anticuerpo-fármaco
WO2025054996A1 (en) 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
CN117417347A (zh) * 2023-09-28 2024-01-19 杭州爱科瑞思生物医药有限公司 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025247255A1 (zh) * 2024-05-28 2025-12-04 映恩生物科技(上海)有限公司 一种抗dll3抗体、抗体药物偶联物及其应用
WO2025247302A1 (zh) * 2024-05-31 2025-12-04 杭州中美华东制药有限公司 一种喜树碱类化合物及其应用
WO2025252101A1 (zh) * 2024-06-05 2025-12-11 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途
WO2025256761A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
WO2025257394A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
EP3130608B1 (en) * 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
KR20190066026A (ko) * 2016-10-07 2019-06-12 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
WO2019034176A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CN110016026B (zh) * 2018-01-08 2022-11-25 上海凌济生物科技有限公司 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CA3114474A1 (en) * 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
MX2022000449A (es) * 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CN116390771A (zh) * 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
JP2023551355A (ja) * 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド 抗腫瘍化合物並びにその調製方法及び使用
WO2022078279A1 (zh) 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
US20250276078A1 (en) 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
CN114569739A (zh) 2020-12-01 2022-06-03 正大天晴药业集团股份有限公司 抗体药物偶联物
EP4628165A3 (en) 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
GEAP202416409A (en) 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof

Also Published As

Publication number Publication date
WO2022068878A1 (zh) 2022-04-07
US20230212182A1 (en) 2023-07-06
CN116239601B (zh) 2023-10-13
CN116199739A (zh) 2023-06-02
CN116239601A (zh) 2023-06-09
US20250367316A1 (en) 2025-12-04
LT4516357T (lt) 2026-04-27
EP4223318A1 (en) 2023-08-09
MX2023003778A (es) 2023-04-26
CA3195515A1 (en) 2022-04-07
CN115175705A (zh) 2022-10-11
US20230086097A1 (en) 2023-03-23
US11952384B2 (en) 2024-04-09
US12168667B2 (en) 2024-12-17
AU2021354823A1 (en) 2023-03-30
US12434077B2 (en) 2025-10-07
EP4516357B1 (en) 2026-02-04
US12091418B2 (en) 2024-09-17
US11685742B2 (en) 2023-06-27
JP2023551355A (ja) 2023-12-08
IL301793A (en) 2023-05-01
CN121944137A (zh) 2026-05-01
TW202214230A (zh) 2022-04-16
US11607459B1 (en) 2023-03-21
CN115925796A (zh) 2023-04-07
CN115925796B (zh) 2024-05-31
US20240174686A1 (en) 2024-05-30
US20240132516A1 (en) 2024-04-25
US20230331738A1 (en) 2023-10-19
KR20230079085A (ko) 2023-06-05
CN116199739B (zh) 2024-12-17
EP4223318A4 (en) 2024-12-18
FI4516357T3 (fi) 2026-03-27
EP4516357A3 (en) 2025-04-16
CN115175705B (zh) 2026-02-03
EP4516357A2 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
DK4516357T3 (da) Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK4075992T3 (da) Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf
IL291467A (en) Fused pyridone compound, and preparation method therefor and use thereof
IL290276A (en) Tetracyclic compound, preparation method and use thereof
DK4053118T3 (da) Substitueret heterocyklisk kondenseret cyklisk forbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3911202T3 (da) Hylstre, applikatorer til vippeforlængelser og fremgangsmåder til fremstilling og anvendelse deraf
DK3524603T3 (da) Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3943491T3 (da) Heteroarylderivat, fremgangsmåde til fremstilling af samme og farmaceutisk sammensætning indeholdende samme som effektiv komponent
DK3884111T3 (da) Tp-fri monopæl og fremgangsmåde til dannelse heraf
DK3888789T3 (da) Hydrocrackingkatalysator, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3424924T3 (da) Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf
DK4241685T3 (da) Medicinsk system og fremgangsmåde til fremstilling deraf
DK3790927T3 (da) Fremgangsmåde, indretning og anvendelse til oparbejdning af i det væsentlige polyalkylenterephthalat
DK3750893T3 (da) Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf
DK4410788T3 (da) Cyanoforbindelse og fremgangsmåde til fremstilling deraf og anvendelse deraf
IL285378A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
DK3947684T3 (da) Forbindelser og fremgangsmåder til at modulere ube3a-ats
DK3897157T3 (da) Plantvækstfremmersammensætning, fremgangsmåder til fremstilling heraf og anvendelser deraf
DK4223752T3 (da) Deutereret hpk1-kinaseinhibitor, fremgangsmåde til fremstilling og anvendelse heraf
DK4000045T3 (da) Renderingsfremgangsmåde og renderingsindretning til udførelse deraf
DK3554179T3 (da) Fremgangsmåde og anordning til trådløs kommunikation
DK3858833T3 (da) Aminonorbornanderivat, fremgangsmåde til fremstilling heraf og anvendelse heraf
DK3816434T3 (da) Vindmølle og dertilhørende fremgangsmåde
DK4034794T3 (da) Annulus-forbindelse og fremgangsmåde til forbindelse
IL286330A (en) Casing for apparatus, apparatus and method